News | May 22, 2024
AstraZeneca plans $1.5 billion ADCs manufacturing facility in Singapore
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Achira is engaged in development and commercialization of PoC medical test kits in India
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
2024 full-year revenue guidance raised by US$ 2 billion
Subscribe To Our Newsletter & Stay Updated
